CASI Pharmaceuticals enters its upcoming results with short interest at its highest level since the position doubled in late March — and a track record of falling after every earnings print on record.
The most striking feature of the short-interest data is what happened around March 24. Short interest as a percentage of free float jumped from roughly 2.8% to above 4.7% in a single session, a near-doubling that has held ever since. The current reading of 4.85% of free float represents a five-week plateau at elevated levels, with shorts adding a further 3% on the week. That step-change in positioning is the clearest signal that informed sellers identified something specific in the late March period — and they have not covered.
The borrow market corroborates the cautious stance, though it is not yet at extremes. Cost to borrow has crept higher through April, now at 11.6% APR after a steady climb from below 11% in mid-month. That is well below the 20% spike seen in late February, which suggests the lending pool is not squeezed but is gradually tightening. The lending pool itself has tightened noticeably since early April: availability has moved from the mid-to-high 60% range toward roughly 68-69%, with the 52-week high utilisation on record at 96.3% — meaning the borrow has been far more constrained in the past year than it is today. With the ORTEX short score at 60.9, the highest it has been in the past two weeks and still climbing, the directional pressure from the lending side remains biased toward further short accumulation rather than a near-term unwind.
The stock's price action adds another layer of tension. CASI closed Wednesday at $0.142, up 7.6% on the day but still down 16.5% on the week — a sharp reversal from a 29% gain over the prior month. That weekly drawdown comes precisely as short interest has continued to build, suggesting the recent sellers are finding momentum. Close peers MNKD and CYTK both saw modest declines on the week, with CYTK off 10% — so the sector backdrop is not helpful. The SEC filing of a Form D on April 28 signals a private placement is in motion, which adds a further potential dilution overhang for existing holders.
The historical earnings reaction pattern at CASI is consistently negative. Across the four most recent prints on record, the stock fell on the day every single time: down 15.1%, 2.4%, 10.9%, and 5.7% respectively. The five-day outcomes were similarly soft, with losses of 22.4%, 4.9%, 7.9%, and 4.1% following those sessions. No single print produced a recovery over the following week. With earnings now flagged for release on Wednesday April 30 — a filing noted by Defence World on April 27 — that pattern is directly relevant to the current positioning.
The ownership structure provides limited offset. Panacea Venture Management holds 22% of shares, Wei-Wu He a further 9.8%, and Zhenfeng Chen 11% — three anchors that collectively own more than 40% of the company and have not moved their positions in recent filings. Institutional coverage beyond the strategic holders is thin, with Renaissance Technologies and Woodline Partners both trimming small positions at year-end. The last meaningful insider transaction on record dates to September 2022 and is too stale to carry weight here.
The week ahead turns on whether Wednesday's earnings release introduces any new catalyst — pipeline update, guidance revision, or equity structure change — that can shift the narrative away from a short book that has been patiently building since late March.
See the live data behind this article on ORTEX.
Open CASI.F on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
